Mar 4, 2026 06:01AM

Mar 3, 2026 09:54AM

Mar 3, 2026 07:30AM

Mar 3, 2026 07:30AM

Mar 3, 2026 04:56AM

Mar 2, 2026 03:25PM

Mar 2, 2026 02:48PM Intellia Therapeutics (NTLA) PT Raised to $15 at RBC Capital

Mar 2, 2026 02:18PM

Mar 2, 2026 02:04PM

Mar 2, 2026 12:28PM

Mar 2, 2026 12:05PM

Mar 2, 2026 10:25AM

Mar 2, 2026 07:30AM

Mar 2, 2026 07:30AM Intellia Therapeutics Announces FDA Lift of Clinical Hold on MAGNITUDE Phase 3 Clinical Trial in ATTR-CM

Feb 26, 2026 01:28PM

Feb 26, 2026 07:30AM

Jan 27, 2026 11:29AM

Jan 27, 2026 08:00AM

Jan 27, 2026 08:00AM

Dec 19, 2025 09:06AM

Nov 18, 2025 08:45AM Longevity-Focused Health Fueling U.S. Anti-Aging Products Market Projected to Reach $27 Billion By 2033

Nov 10, 2025 03:17PM

Nov 10, 2025 03:17PM

Nov 8, 2025 05:13PM

Nov 8, 2025 05:13PM

Nov 7, 2025 08:56AM

Nov 6, 2025 04:00PM

Oct 31, 2025 09:54AM FDA Clears Way for Faster Personalized Gene Editing Treatments

Oct 31, 2025 07:27AM

Oct 30, 2025 04:55AM

Oct 29, 2025 04:24PM

Oct 28, 2025 06:26AM

Oct 27, 2025 07:31AM

Oct 27, 2025 07:30AM

Sep 18, 2025 07:30AM Intellia completes enrollment in phase 3 study of HAE gene therapy

Sep 18, 2025 07:30AM

Aug 30, 2025 04:00PM

Jun 15, 2025 10:45AM

May 29, 2025 07:49AM

May 8, 2025 07:30AM

Apr 3, 2025 07:35AM

Apr 3, 2025 07:30AM Intellia Therapeutics Announces First Patient Dosed in the MAGNITUDE-2 Phase 3 Study of Nexiguran Ziclumeran (nex-z), a One-Time Gene Editing-Based Treatment for Transthyretin (ATTR) Amyloidosis with

Mar 26, 2025 07:30AM

Mar 26, 2025 07:30AM

Feb 27, 2025 03:04PM

Feb 27, 2025 07:30AM

Jan 22, 2025 07:31AM

Jan 22, 2025 07:30AM

Nov 30, 2024 04:00AM Is Trump 2.0 good or bad for healthcare stocks?

Nov 25, 2024 07:30AM

312,667 total articles have been posted to this entity.

Click Here to Sign-Up for StreetInsider.com Premium to View All